Jaguar Health, Inc.

Entry into a Material Definitive Agreement. License Agreement On January 12, 2026 (the “Effective Date”), Napo Pharmaceuticals, Inc. (“Napo”), a wholly-owned su

Regulation FD Disclosure. On January 12, 2026, the Company issued a press release announcing Napo’s entry into the License Agreement. A copy of the press releas

Financial Statements and Exhibits. Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 10.1 * License Agreement. 10.2 * Supply Agreement. 99.1